Dyspnea in patients with interstitial lung disease
Conditions
Interventions
Single subcutaneous injection of morphine 1mg or 2mg.
Sponsors
Non-Profit Organization JORTC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Inpatients with interstitial lung diseases diagnosed by more than 1 radiologist and more than 2 respiratory physicians based on clinical course, chest CT, lung function test and so on. 2. Patients with severe dyspnea at rest after standard treatment for dypnea 3. Patients who have the following data at baseline: AST <= 100 IU/L ALT <= 100 IU/L T-BIL <= 2.0 mg/dL SPO2 >= 90 % (Oxygen is allowed) PaCO2 <= 50 Torr (Oxygen is allowed) 4. Patients aged 20 years-old or older at the time of obtaining informed consent 5. Patients with expected survival of 1 month or longer 6. Patients with lucidity and capability of communication and without cognitive inpairments 7. Patients who agree to participate the study with written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients with contraindication of morphine (ex. allergy for morphine and history of severe adverse effects of morphine) 2. Patients who use opioid 3. Patients with left heart failure by echocardiography. 4. Patients with acute respiratory failure ( bacterial pneumonia, acute excerbation of interstitial pneumonia and so on). 5. Patients with active infection that causes dyspnea 6. Patients with lung cancer that causes dyspnea 7. Patients with pneumothorax 8. Patients who uses invasive positive airway pressure ventilation. Patients who uses nasal high flow were not excluded 9. Patients who changed the way of intaking of corticosteroids, immunosuppressant, bronchodilators, vasodilators and anxiolytics within two days before enrollment of the study 10. Patients who have or had drug abuse or drug dependence 11. Patients who are pregnant or possibly pregnant 12. Patients who are judged to be innapropriate for the study by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory depression and hypotension defined in the protocol and adverse effect >= Grade 3 (CTCAE) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Dyspnea NRS change between before and after morphine treatment 2. Heart rate before and after treatment 3. PaO2 and PaCO2 before and after treatment. 4. Number of vomitting 5. Derilium 6. Sedation 7. Adverse effect between 60 minutes and 24 hours after treatment. | — |
Countries
Japan
Contacts
Public ContactYoshinobu Matsuda
National Hospital Organization Kinki-Chuo Chest Medical Center Department of Psychosomatic Internal Medicine
Outcome results
None listed